Effect of Melatonin in Pediatric Hemodialysis Patients

Inflammation Clinical Trial

Official title:

Effect Of Melatonin On The Clinical Outcome In Pediatric Hemodialysis Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05570526
• Other study ID #: RHDIRB2020110301 REC#99
• Status: Recruiting
• Phase: Phase 3
• Start date: December 1, 2022
• Est. completion date: March 25, 2023

Study information

• Verified date: January 2023
• Source: Ain Shams University
• Contact: Ghadeer Amged, BSc
• Phone: +201002217996
• Email: ghadeer.amgad[@]pharma.asu.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Prospective, randomized, double-blinded, placebo-controlled trial will be conducted at the pediatric dialysis unit, Children's Hospital, Ain Shams University in order to investigate the benefits of melatonin supplementation on oxidative stress, inflammation and to assess sleep quality by using PSQI questionnaire in pediatric hemodialysis patients.

Description:

1. Patients will be recruited and evaluated for eligibility.

2. Patients who meet the eligibility criteria will be randomly assigned to either placebo or intervention group.

3. Patient demographics, clinical characteristics and full medical and medication history:

will be obtained at baseline and every 4 weeks after the beginning of the study.

4. Blood samples will be withdrawn from each patient before the dialysis session for assay of each of the following:

1.Oxidative stress marker malondialdehyde (MDA) by ELISA assay. 2. Inflammatory marker level nuclear factor kappa B (NF-KB) by ELISA assay 3. Complete blood picture (CBC). 4. Lipid profile (total cholesterol(TC), triglycerides(TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) 5)Safety will be assessed weekly after the beginning of the study by monitoring the side effects or any adverse drug reactions.

• A total of (40) patients on regular HD will be enrolled in the study. These patients will be randomly assigned in a 1:1 ratio into two groups:

• The first group (n=20):The patients in the first group will receive a total daily dose of 5mg of melatonin tablets 1-hour before bedtime for 12 weeks.

• The second group (n=20): The patients will receive one tablet of placebo for the same duration.

• All subjects will sign an informed consent statement prior to inclusion in the study.

• All subjects will be followed up weekly for 12 weeks and blood samples will be withdrawn at baseline and the end of the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: March 25, 2023
• Est. primary completion date: March 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

All patients will be assessed for eligibility according to the following inclusion and exclusion criteria:

Inclusion Criteria:

1. Male or female patients age from 6-18 years old.

2. Undergoing regular HD for at least 6 months prior to enrollment

3. Not enrolled in any other clinical trial.

4. Judged by the physician to be physically stable

Exclusion Criteria:

1. Patients receiving anti-epileptics.

2. Patients with some autoimmune conditions as SLE, RA or post-organ transplant

3. Patients taking immunosuppressants.

4. Patients taking warfarin.

5. Patients receiving vitamin E, green tea or zinc during the past 3 months

6. Patients with malignancy and/or active inflammatory disease

7. Patients with mal absorption, mental retardation or psychiatric illness.

8. Patients who had hemorrhagic episodes or received blood transfusion in the past 3 months prior to the enrollment.

Related Conditions & MeSH terms

• Hemodialysis Complication
• Inflammation
• Oxidative Stress

Intervention

Dietary Supplement:
• Melatonin
Puritan's Pride ® Melatonin 5mg tablets orally once daily.

Other:
• Placebo
Placebo tablet once daily.

Locations

Country	Name	City	State
Egypt	Ain Shams University Hospitals	Cairo	Abbasseya

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in baseline Malondialdehyde (MDA) level.	Oxidative stress marker	At baseline and at 12 weeks.
Secondary	Change in baseline nuclear factor kappa B (NF-KB) level.	Inflammatory marker	At baseline and at 12 weeks.
Secondary	Change in sleep quality by using Pittsburgh Sleep Quality Index (PSQI) questionnaire	Sleep quality assessment using the validated Arabic version of PSQI questionnaire.	At baseline and at 12 weeks.